• Is male or female and ≥55 and ≤95 years of age living in the community or in an institutionalized setting

• Meets clinical criteria for possible or probable AD based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria

• Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association (IPA)

• Has either blood-based biomarker or documented evidence (e.g. positron emission tomography, cerebrospinal fluid biomarker) indicating amyloid plaque deposition and neuropathologic change consistent with AD

• Has a prior magnetic resonance imaging or computed tomography scan of the brain that is consistent with the diagnosis of AD

• Meets revised criteria for psychosis in major or mild neurocognitive disorder as per International Psychogeriatrics Association

• MMSE score ≥6 and ≤24

• Psychotic symptoms for at least 2 months

• Lives in a stable place of residence and there are no plans to change living arrangements

• Has a designated study partner/caregiver

• Able to complete all study visits with a study partner/caregiver

• Must be on a stable dose of cholinesterase inhibitor or memantine, if applicable